The long-term effect of dupilumab on dyspnea, sleep, and activity in oral corticosteroid-dependent severe asthma
Sher L, Passalacqua G, Taillé C, Cohn L, Daizadeh N, Pandit-Abid N, Soler X, Khodzhayev A, Jacob-Nara J, Deniz Y, Rowe P, Nag A, Zhang Y. The long-term effect of dupilumab on dyspnea, sleep, and activity in oral corticosteroid-dependent severe asthma. Annals Of Allergy Asthma & Immunology 2022, 130: 298-304. PMID: 36509407, DOI: 10.1016/j.anai.2022.12.002.Peer-Reviewed Original ResearchConceptsPlacebo-treated patientsSevere asthmaActivity limitationsDose reductionAQLQ scoresDupilumab groupWeek 24Open-label extensionProportion of patientsType 2 inflammationHuman monoclonal antibodyQuality of lifeOral corticosteroidsOCS useInterleukin-4Long-term effectsAsthmaPatientsSymptomsMonoclonal antibodiesSleepReceptor componentsDupilumabDyspneaWeeks